______________________________________________________

A Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer

Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer

Summary

This is a multicenter, randomized, double-blind, Placebo-controlled Phase 3 study to compare the PFS of subjects with 131I-refractory DTC and radiographic evidence of disease progression within the prior 12 months, treated with E7080 24 mg by continuous once daily (QD) oral dosing versus Placebo.

Phase: Phase 3

Patients Recruitment will be started in June - July 2011

The study is posted on ClinicalTrials.gov. Please see link below for more information on this study:

http://clinicaltrials.gov/ct2/show/NCT01321554?term=thyroid+cancer&recr=Open&rank=27

Study will be conducted at Jersey Shore University Medical Center. We are one of the several sites in the States.

I will be a Principal Investigator at Jersey Shore University Medical Center for this study.

Co-Investigators: Dr Sunil Asnani, MD (Endocrinology), Dr Danielle Lann, MD (Endocrinology)

For eligibility, recruitment or questions please contact:

Maureen Kinsley, RN, BSN, OCN, Clinical Research coordinator,

Jersey Shore University Medical Center

732-776-3398 (T)

732-776-4973 (F)